Mega-doses of L-ascorbic acid alter the antineoplastic effects of ionizing radiation in EMT6 cells in vitro by Lund, Karina
Yale University
EliScholar – A Digital Platform for Scholarly Publishing at Yale
Yale Medicine Thesis Digital Library School of Medicine
11-15-2006
Mega-doses of L-ascorbic acid alter the
antineoplastic effects of ionizing radiation in EMT6
cells in vitro
Karina Lund
Follow this and additional works at: http://elischolar.library.yale.edu/ymtdl
This Open Access Thesis is brought to you for free and open access by the School of Medicine at EliScholar – A Digital Platform for Scholarly
Publishing at Yale. It has been accepted for inclusion in Yale Medicine Thesis Digital Library by an authorized administrator of EliScholar – A Digital
Platform for Scholarly Publishing at Yale. For more information, please contact elischolar@yale.edu.
Recommended Citation
Lund, Karina, "Mega-doses of L-ascorbic acid alter the antineoplastic effects of ionizing radiation in EMT6 cells in vitro" (2006). Yale









Mega-doses of L-ascorbic acid alter the antineoplastic effects of 









A Thesis Submitted to the 
Yale University School of Medicine 
in Partial Fulfillment of the Requirements for the 

















MEGA-DOSES OF L-ASCORBIC ACID ALTER THE ANTINEOPLASTIC EFFECTS 
OF IONIZING RADIATION IN EMT6 CELLS IN VITRO.  Karina Ann Lund 
(Sponsored by Dr. Sara Rockwell).  Department of Therapeutic Radiology, Yale 




Despite the common usage of high-dose vitamin C among breast cancer patients, 
the published medical literature is not in agreement as to how mega-dose vitamin C may 
interact with conventional therapy to affect clinical outcomes.  The purpose of this study 
was to investigate the interaction of mega-dose vitamin C with radiation therapy and with 
doxorubicin in the treatment of breast cancer.  Cultures of EMT6 mouse mammary tumor 
cells were treated concurrently with varying dose of vitamin C and either radiation or 
doxorubicin.  A clonogenic assay was then performed to determine the surviving fraction 
of the cells.  The surviving fractions of cells in cultures receiving different doses of 
vitamin C were compared among themselves as well as with controls and dose response 
curves were generated.  Results show that ascorbic acid administered in concentrations of 
1 mM or 10 mM 4 hours before x-irradiation protected the cells from radiation-induced 
cytotoxicity.  The dose-modifying factors for 1 mM and 10 mM ascorbic acid as 
compared to controls were 1.23 and 1.37 respectively.  These results support the 
hypothesis that mega-dose vitamin C, when taken concurrently with radiation therapy, 
protects cancer cells from the cytotoxic effects of ionizing radiation.  No evidence was 
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Prevalence of Complementary and Alternative Medicine Use among Cancer 
Patients 
 
 The National Center for Complementary and Alternative Medicine 
(http://nccam.nih.gov/), a component of the National Institutes of Health, defines 
complementary and alternative medicine (CAM) as “a group of diverse medical and 
health care systems, practices, and products that are not presently considered to be part of 
conventional medicine.”  Complementary medicines are used concomitantly with 
conventional medicine, whereas alternative medicines are used to substitute for 
conventional medicine.     
 
It is well documented that CAM is widely used by cancer patients.  In 1998, Ernst 
and Cassileth published a review of the literature documenting the prevalence of CAM 
use among cancer patients.  They reviewed 26 surveys from 13 countries which found a 
prevalence of CAM use among adult cancer patients ranging from 7 to 64 percent with an 
average prevalence of 31.4 percent (1). The study authors attribute this wide variability to 
a lack of specificity in the definition of CAM within studies and inconsistency in its 
definition between studies.  Nevertheless, they conclude that the use of CAM by cancer 
patients is both common and widespread.  That same year, a national survey conducted 
by Eisenberg et al. found that the prevalence of CAM use among the general population 
increased from 33.8 percent in 1990 to 42.1 percent in 1997 (p ≤ 0.001) (2).  According 
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to the survey results, one of the therapies that increased the most during that time was 
megavitamins, defined by Dictionary.com as “a dose of a vitamin greatly exceeding the 
amount required to maintain health.”    
 
Since 1998, multiple new studies have been published which further support the 
high prevalence of CAM use among cancer patients.    In a study of CAM use by breast 
cancer survivors in Ontario, Canada, 66.7 percent of the survey respondents reported 
using CAM (3).  In a cohort study of 480 patients in Massachusetts with newly diagnosed 
early-stage breast cancer, 10.6 percent of the study participants had used CAM prior to 
being diagnosed with breast cancer, and 28.1 percent initiated new use of CAM after 
surgery for their cancer (4).  A 2004 survey of 500 women with breast or gynecologic 
cancers at the M.D. Anderson Cancer Center found that 48 percent of the women used 
CAM (5).  In a study of patients with advanced-stage breast cancer, 73 percent of patients 
reported using CAM (6).  Given the high prevalence of CAM use among cancer patients, 
an understanding of the interactions of CAM with conventional cancer therapies is 




 Vitamin C (ascorbic acid) is an important water-soluble dietary vitamin.  It is 
absorbed in the distal small intestine via a sodium-dependent cotransport mechanism ( ) 
and excreted renally.
7
  The recommended daily allowance of vitamin C for females is 
75 mg and for males is 90 mg; daily intake should not exceed 2000 mg (8).  Nearly all of 
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the vitamin C ingested is absorbed into the circulation up to a daily intake of 100 mg (9).  
However, as ingestion increases above this dose, a progressively smaller percentage of 
dietary vitamin C is absorbed (10).  Scurvy is a clinical syndrome that develops with 
vitamin C deficiency.  Symptoms of scurvy include:  petechiae, ecchymoses, bleeding 
gums, hyperkeratosis, arthralgias, impaired wound healing, neuropathy, weakness, 
malaise and depression (11).  Symptoms of vitamin C overdose include renal calculi, 
nausea, gastritis and diarrhea (8). 
 
Although the mechanism of action of vitamin C is not yet fully understood, much 
has been learned about the biochemical functions it performs, which are many and varied.  
Vitamin C plays an important role in collagen synthesis and tissue repair ( ).  Many of 
the symptoms observed in scurvy, for example, are due to impaired collagen synthesis 
secondary to vitamin C deficiency.  In the gut, vitamin C enhances iron absorption ( ).   
Once absorbed, vitamin C acts as a reversible reducing agent in a variety of biochemical 
reactions involving iron and copper, in some cases resulting in the alteration of enzyme 
activity ( ).  The antioxidant properties of vitamin C make it capable of stabilizing 






Nobel laureate Linus Pauling’s 1979 book, Cancer and Vitamin C, opened the 
public debate over the effectiveness of vitamin C in the prevention and treatment of 
cancer.  In this book, Pauling and his co-author, Ewan Cameron, argued that mega-dose 
vitamin C improves clinical outcomes in cancer patients ( 14 ).  In support of their 
argument, Cameron and Pauling presented the results of a study of 100 patients with 
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terminal cancer.  These patients were given 10 g of vitamin C daily and their survival was 
compared with that of 370 case controls.  Results showed a remarkable increase in 
survival time among the patients treated with high-dose vitamin C.  The study was 
criticized for exhibiting selection bias as the study cases were all Dr. Cameron’s patients 
whereas case controls were taken from historical chart reviews of patients treated at a 
different hospital.  A group at the Mayo Clinic subsequently attempted to confirm 
Pauling’s findings by conducting a prospective, randomized, double-blind trial 
comparing high-dose vitamin C with placebo in terminal cancer patients who had been 
previously treated with conventional therapy (15).  The Mayo Clinic group found instead 
that the patients in the vitamin C arm of the study deteriorated more quickly than those in 
the placebo arm.  After receiving criticism from Dr. Pauling for including in their study 
patients who had a prior history of chemotherapy (16), the Mayo Clinic group conducted 
a second study with identical treatment arms but in patients who had not previously been 
exposed to conventional cytotoxic chemotherapy (17, 18).  Again, no benefit of vitamin 
C was observed.   
 
A significant amount of research has recently sought to answer the question of 
whether vitamin C may have a role as an adjuvant therapy in the treatment of cancer 
either to protect normal tissues or to potentiate antineoplastic activity.  Current literature 
will be reviewed separately for studies investigating the interaction of vitamin C with 





 Radiation therapy is widely used in the treatment of human cancers and certain 
other hyperproliferative diseases.  Greater than 60 percent of cancer patients undergo 
radiation therapy at some point during the course of their illness.  Radiation therapy can 
be used with curative intent, for palliation of symptoms or as adjuvant therapy (19).  
Adjuvant radiation therapy may be used to shrink a tumor prior to surgery as well as to 
kill remaining malignant cells following surgery.  Chemotherapy given prior to or 
concomitantly with adjuvant radiotherapy may make tumors more sensitive to the effects 
of radiation.  Two of the most common methods of delivering radiation to patients are 
external beam radiation, which uses a linear accelerator, cobalt-60 irradiator or other 
machine to deliver radiation from outside the body to the tumor, and brachytherapy in 
which γ-radiation is delivered directly to the tumor from within the body ( 20 ).  
Brachytherapy implants can be intracavitary, interstitial or intravenous.  Of course, the 
goal in devising any radiation treatment plan is to kill cancer cells with the greatest 
possible efficacy while minimizing damage to normal tissue. 
 
 When radiation is absorbed by living tissue, energy may be transferred to an 
electron causing excitation of that electron.  Radiation that has sufficient energy to eject 
an orbital electron from the atom is referred to as ionizing radiation.  There are several 
different types of ionizing radiation that are used clinically in therapeutic radiology.  
X-rays and γ-rays are both electromagnetic radiations with similar spectrums of 
frequency and energy, which produce ionization (19, 20).  When orbital electrons change 
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between high-energy and low-energy states, x-rays are emitted that contain the energy 
released in these transitions.  Gamma rays are emitted from the nuclei of certain 
radioactive elements as they decay.  Particulate radiations (i.e. electrons, protons, 
α-particles, neutrons or other particles accelerated to high velocities) can also produce 
ionization (19, 20).  Both electromagnetic and particulate radiations are used in cancer 
therapy. 
 
X-ray photons are typically absorbed by tissue in one of two ways:  by Compton 
scattering or by photoelectric absorption (20, 21).  Pair production, a third way in which 
a photon can be absorbed, results in the production of an electron-positron pair.  This 
occurs only when the photon energy is greater than 1.02 MeV, a condition that is not met 
in the experiments conducted for this thesis.  In Compton scattering, which dominates at 
high energies, the incident photon transfers a portion of its energy to a loosely bound 
electron of an atom of the absorbing tissue causing that electron to be ejected from the 
atom as a fast-moving particle (see Figure 1).  The photon, deflected from its original 
path, continues with the remaining energy.  In contrast, when radiation is absorbed by the 
photoelectric process, which dominates at low energies, the incident photon interacts with 
a tightly bound electron, transferring all of its energy to that electron (see Figure 2).  The 
resultant fast-moving electron, having been ejected from the atom, has a kinetic energy 
equal to the energy of the incident photon minus the electron’s binding energy.  The 
vacancy left by the ejected electron is filled either by an outer orbital electron from 
within the same atom or by an electron from outside the atom.  This filling of the vacancy 










FIGURE 1.  Absorption of an x-ray photon by Compton scattering.  The incident 
photon transfers a portion of its energy to a loosely bound electron of an atom of the 
absorbing tissue causing that electron to be ejected from the atom as a fast-moving 
particle.  The photon, deflected from its original path, proceeds with reduced energy.  
Key:  e- represents an electron; p+ represents a proton; n represents a neutron.  This 
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FIGURE 2.  Absorption of an x-ray photon by the photoelectric process.  The 
incident photon interacts with a tightly bound electron, transferring all of its energy to 
that electron and ejecting the electron from the atom.  The vacancy left by the ejected 
electron is filled either by an outer orbital electron from within the same atom or by an 
electron from outside the atom.  This filling of the vacancy causes the emission of 
characteristic x-rays.  Key:  e- represents an electron; p+ represents a proton; n represents 
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by Compton scattering or by the photoelectric process, the production of fast-moving free 
electrons is essential to cause damage to critical molecules such as DNA. 
 
Ionizing radiation can damage DNA either directly or indirectly (20).  If an 
incident photon happens to be absorbed by a critical molecule such as DNA, that photon 
can cause direct biological damage.  The vast majority of radiation-induced damage, 
however, is produced indirectly.  In this case, free electrons produced by photon 
absorption interact with nearby molecules, commonly with water, to produce free radicals 
(22).  Free radicals are highly reactive atoms or molecules that carry an unpaired orbital 
electron in an outer shell.  These free radicals initiate a chain of reactions with other 
nearby molecules to produce a large number of ions, free radicals and other chemically 
reactive species that then go on to damage critical cellular molecules, most importantly 
DNA (22).   
 
The damaging biologic effects of indirectly acting radiation can be modified by 
chemical agents that act as either radiosensitizers or radioprotectors (20, 22, 23).  This is 
in contrast to the direct action of radiation that cannot be modified by these agents.  A 
radiosensitizer is a chemical agent that increases the damage induced by a given dose of 
radiation, whereas a radioprotector prevents or diminishes the damage produced by the 
radiation.  In other words, radiosensitizers cause decreased cell survival following 
radiotherapy, steepening the slope of the radiation dose-response curve; while 
radioprotectors cause increased cell survival, decreasing the slope of the curve (see the 
Materials and Methods section for more information on dose-response curves).  
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Molecular oxygen is an example of a radiosensitizer.  Oxygen is a frequent participant in 
chemical reactions that produce the ions and free radicals which go on to cause biologic 
damage.  On the other hand, chemical compounds that scavenge free radicals can protect 
cells and tissues from the damaging effects of radiation.  Antioxidants, because of their 
properties as free radical scavengers, have been studied as potential clinically important 
radioprotectors (23).  
 
 In order to study the effects of agents that might alter the cellular response to 
radiation, it is important to have a precise definition of what we mean by “cell survival.”  
When discussing the survival of cancer cells, the clinically relevant question to ask is 
whether the cells have the capacity to grow and form a tumor, to locally invade 
surrounding tissues, or to metastasize to distant sites.  After being irradiated, a given 
tumor cell might continue to live and carry on with its metabolic functions; but if it is 
unable to divide indefinitely to produce a large number of daughter cells, it has become 
clinically inconsequential and can be considered dead.  Hall refers to this phenomenon as 
“reproductive death” (20).  In order to be considered a survivor, a cell must maintain the 
capacity to produce a colony of new cells.  In other words, cell survival is defined in 
terms of clonogenicity.   
 
Current in vitro data available from the scientific literature is inconclusive in 
respect to the possible interaction between high-dose vitamin C and radiotherapy.  In 
vitro experiments conducted by Witenberg et al. demonstrated that preincubation with an 
ascorbic acid derivative protects HL60 myeloid leukemia cells against x-irradiation-
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induced apoptosis (24).  In a study of normal human lymphocytes treated with radiation 
in vitro, Konopacka and Rzeszowska-Wolny found evidence for a radioprotective effect 
of vitamin C at all tested concentrations when the vitamin was administered after 
irradiation ( 25 ). When given prior to irradiation, vitamin C was found to have a 
significant protective effect at low concentration (1 µg/mL) and a sensitizing effect at the 
highest concentration tested (20 µg/mL), though the sensitizing effect was not significant.  
Ortmann et al. studied the effect of vitamin C on radiation-induced apoptosis in normal 
human lymphoblastic cells in vitro (26).  When given prior to irradiation, vitamin C had 
a slight but statistically significant radiosensitizing effect at 100 µM, the highest 
concentration tested.  When given immediately after irradiation, vitamin C had a 
radioprotective effect at 0.01 µM, the lowest concentration tested.  
 
 The cumulative data obtained from animal models have been similarly 
inconclusive.  In their study of Ehrlich ascites tumor cells in vivo, Koch and Biaglow 
found that dehydroascorbate, a metabolite of vitamin C, sensitized the tumor cells to 
radiation (27).  Tewkif et al. administered ascorbic acid to mice in vivo and studied its 
effects on solid tumor growth and on tumor control by radiation (28).  They found that 
tumor growth was significantly faster in control mice compared to mice receiving vitamin 
C.  Additionally, tumor control by radiation was better in the ascorbic acid group than in 
controls.  Okunieff performed in vivo experiments in mice investigating the effect of 
high-dose ascorbic acid on the radiation response of both normal tissues and transplanted 
tumor (29).  Results showed that vitamin C protected normal bone marrow and skin from 
radiation damage without affecting the dose of radiation required to control 50 percent of 
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tumors or to achieve remission. Sarma and Kesavan found vitamin C to have a protective 
effect against γ-ray-induced chromosomal damage in mice as evidenced by a reduction in 
the frequency of micronuclei and chromosomal aberrations in the bone marrow cells of 
vitamin C-treated mice compared to controls after whole body γ-irradiation ( 30 ).  
Konopacka et al. conducted in vivo experiments in mice investigating the modifying 
effect of vitamin C on the clastogenic activity of γ-rays as measured by the number of 
micronuclei in bone marrow polychromatic erythrocytes and exfoliated bladder cells (31).  
When given before irradiation, vitamin C was found to be a radioprotector at low doses 
(50-100 mg/kg/day) and a radiosensitizer at the highest dose tested (400 mg/kg/day).  
When given after irradiation at the same high dose, however, vitamin C acted as a 
radioprotector. 
 
Given the high prevalence of CAM use among cancer patients and the 
inconclusive results of the experimental data to date, the question of whether high-dose 
vitamin C alters the efficacy and/or toxicity of radiotherapy is an important clinical 




 Doxorubicin is an intravenously administered chemotherapeutic agent used 
commonly in the treatment of many cancers including cancers of the breast, endometrium 
and thyroid as well as both acute lymphocytic and acute myelogenous leukemias, 
Hodgkin’s and non-Hodgkin’s lymphomas, osteosarcoma, Kaposi’s sarcoma, and soft-
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tissue sarcomas.  Acute and reversible adverse effects of doxorubicin include 
myelosuppression, nausea, vomiting and cardiac arrhythmias.  The most important 
adverse effect of the drug, however, which may develop after weeks or months of 
repeated treatments with doxorubicin is irreversible chronic cardiomyopathy.  The 
development of cardiomyopathy secondary to doxorubicin is related to the total 
cumulative dose of drug given (32).  For this reason, it has been recommended that 
patients receive a total cumulative dose no greater than 550 mg/m2 of body surface area 
(32) and that cardiac performance be assessed prior to the initiation of, during, and after 
completion of therapy with doxorubicin (33). 
 
Doxorubicin is classified as an anthracycline antibiotic.  Although its mechanism 
of action is not fully understood, doxorubicin is believed to cause its antineoplastic 
effects through a multifactorial, complex process.  Multiple mechanisms of action have 
been proposed.  For example, it has been postulated that doxorubicin alters DNA in a 
number of ways including: inducing DNA strand breaks, inducing DNA cross-links, 
interfering with DNA strand separation and helicase activity, or inhibiting DNA synthesis 
by intercalating with the sugar phosphate backbone or inhibiting DNA polymerase (34).  
A second category of proposed mechanisms has to do with disruption of membranes.  
Doxorubicin has been found to cause a dose-related decrease in membrane fluidity (35) 
as well as altering other membrane properties (36).  A third major class of hypothesized 
mechanisms involves the generation of free radicals and other reactive oxygen species 
(34).  This is one of the main mechanisms believed to be responsible for the 
cardiotoxicity of the drug.   
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In theory, free radical scavengers (such as antioxidants, which bind to free 
radicals thereby preventing oxidative damage) could protect cardiac and other normal 
tissues from the free radical-mediated damage caused by doxorubicin.  The resultant 
reduction in adverse effects could allow for the use of increased drug doses leading to a 
possible improvement in tumor control.  However, consideration must be given to the 
possibility that any protection provided to normal tissues may also be afforded to the 
tumor, essentially protecting cancer cells from the very treatment intended to destroy 
them. 
 
 Cell culture and animal model data examining the interaction of vitamin C and 
doxorubicin is inconclusive.  Wells et al. studied the effect of L-ascorbic acid 
2-phosphate, a less active and more stable ascorbate derivative, on doxorubicin toxicity in 
two strains of human breast cancer cells, one that is doxorubicin-sensitive and one that is 
doxorubicin-resistant.  Whereas L-ascorbic acid 2-phosphate had no effect on the survival 
of cells of the doxorubicin-sensitive strain, it caused enhanced resistance in cells of the 
doxorubicin-resistant strain (37).  A separate study of human breast cancer cells treated 
in vitro with doxorubicin found that vitamin C potentiated the cytotoxicity of doxorubicin 
( 38 ).  Shimpo and Fujita et al. studied the effects of ascorbic acid and two of its 
derivatives, CV-3611 and ascorbyl palmitate, on both the antitumor activity and the 
cardiotoxicity of doxorubicin in mice and guinea pigs (39, 40).  They found that the 
incidence of doxorubicin-induced cardiomyopathy was significantly decreased in the 
animals receiving ascorbic acid while antitumor activity was not reduced.  Furthermore, 
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mice and guinea pigs treated with any of the three forms of vitamin C together with toxic 
doses of doxorubicin lived longer than those treated with doxorubicin alone.  Atunes and 
Takahashi investigated the effect of vitamin C on normal bone marrow cells of the Wistar 
rat treated with doxorubicin in vivo (41).  They found that only the lowest studied dose of 
vitamin C demonstrated a protective effect as measured by total number of chromosome 
aberrations.  The highest doses of vitamin tested produced no change in outcome 
compared to control.  
 
Given the high prevalence of CAM use among cancer patients and the 
contradictory nature of the data available to date, the question of whether high-dose 
vitamin C alters the efficacy and/or toxicity of doxorubicin is an important clinical 
question to answer so that clinicians may better advise their patients. 
 
EMT6 In Vivo – In Vitro Tumor System 
 
Given the technical and ethical limitations of studying tumor response to therapy 
in humans, experimental oncology has been faced with the challenge of developing 
animal and cell culture models for human cancers that lend themselves to 
experimentation.  Spontaneous tumors, while valuable experimental models, present a 
high level of variability, offer only small numbers of homogeneous tumors for 
experimentation, and are difficult to use in the measurement of therapeutic efficacy of 
different treatments.  Inbred rodent strains make available large numbers of genetically 
identical animals, which have the benefit of greatly reducing variability in in vivo 
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experiments.  These animals can be used to study transplanted tumor lines or to induce 
and study autochthonous tumors, tumors studied in the host of origin.  In vitro models 
allow for even greater control over the experimental environment and interventions as 
well as more precise assays of cell survival.  Despite having ideal characteristics for 
experimental manipulation, however, cells studied in vitro are not a perfect model for 
tumors existing in vivo.  Unlike cells grown in culture, cells within a single tumor exist in 
different states of proliferation and in a variety of different environments in terms of 
oxygen concentrations, pH, nutrient availability and other parameters.  In vivo-in vitro 
cell lines have been developed to address this problem. 
 
In vivo-in vitro cell lines are transplanted tumor cell lines that have been selected 
or adapted for growth in cell culture. Prior to the development of an in vivo-in vitro tumor 
system, data from cell culture was compared with that from animal experiments using 
different cell lines.  The great advantage of an in vivo-in vitro tumor system is that it 
allows for study of a single cell line both in culture and in animals, thereby benefiting 
from the advantages offered by both models.  For example, cells can be injected into 
research animals and the subsequent tumors studied and treated in an environment that 
closely resembles that of spontaneous human tumors.  These same solid tumor cells, 
having been treated in vivo, can then be suspended, plated and assayed in vitro for cell 
survival. 
 
 The EMT6 cell line, used in all experiments of the present study, is an in vivo-in 
vitro tumor system first isolated and characterized by Rockwell et al. (42).  The original 
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tumor was the primary mammary tumor KHJJ-1 that arose in a BALB/c mouse.  This 
tumor was serially transplanted in BALB/c mice and then put into culture.  After multiple 
in vitro passages, the cell line was cloned and several of the clones characterized.  The 
sixth clone, EMT6, was selected for having desirable characteristics for a model system 
to be used in experimental oncology.  The EMT6 cell line grows rapidly in culture with a 
doubling time of about 12 to 16 hours, has a high plating efficiency of about 80 percent, 
and produces tumors when injected into BALB/c mice (43).  Because of its lack of 
differentiation, the EMT6 tumor cell line, like all in vivo-in vitro tumor systems, should 
be considered a model for aggressive, rapidly growing tumors in general as opposed to 
being a model for a narrower subset of human tumors which share the same histology as 
the EMT6 cell line. 
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STATEMENT OF PURPOSE 
 
To investigate the potential clinical significance of the concomitant use of 
mega-dose vitamin C with conventional cancer therapies, I asked whether ascorbic acid 
alters the response of breast cancer cells in vitro either to radiation or to doxorubicin, a 
commonly used antineoplastic agent.  The interactions of varying doses of L-ascorbic 
acid with ionizing radiation and doxorubicin were analyzed using cultures of EMT6 
mouse mammary carcinoma cells, the specific aim being to elucidate any modifying 




MATERIALS AND METHODS  
 
Cell Culture  
 
 EMT6 mouse mammary carcinoma cells (sub-line EMT6-Rw) were used for all 
experiments.  Experimental cell cultures were initiated using exponentially growing cells 
from already established cell lines.  These cells were incubated at 37ºC in a humidified 
atmosphere of 95 percent air and 5 percent CO2.  Stock cultures were routinely passed by 
laboratory personnel using Waymouth’s medium supplemented with 15 percent serum 
(made up of fetal clone and fetal bovine serum at a 1:1 ratio), and antibiotics (100 U/mL 
penicillin-G, 100 µg/mL streptomycin sulfate, 5 µg/mL gentamycin and 0.125 µg/mL 
fungizone).  To ensure tight control of L-ascorbic acid levels, experimental cultures were 
grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10 percent 
dialyzed fetal bovine serum (dFBS), neither of which contain ascorbic acid or other 
redox-active small molecules.  The experimental culture medium was additionally 
supplemented with the same antibiotics as the Waymouth’s medium described above.  
All cell cultures were grown in 60-mm Petri dishes. 
 
Drugs and Radiation 
 
 Powdered L-ascorbic acid, obtained from Sigma-Aldrich, was stored at room 
temperature and protected from light to prevent degradation.  Immediately prior to each 
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experiment, ascorbic acid powder was dissolved in sterile phosphate-buffered saline 
(PBS) at a pH of 7.1 and sterilized by filtration through a 0.22-µm filter.  The solution 
was then protected from light until it was added to the cell culture medium.  Petri dishes 
were immediately returned to the incubator after addition of ascorbic acid to minimize 
light exposure. 
 
 Cells were irradiated with graded doses of radiation using 250 kVp x-rays (15 mA, 
2 mm A1 equivalent filtration) from a Siemen’s Stabilipan x-ray therapy machine at a 
dose rate of 1.1 Gy/min.   
 




Preliminary growth studies were performed to determine the toxicity of 
L-ascorbic acid in the absence of radiation or antineoplastic agents.  EMT6 mouse 
mammary tumor cells were harvested from exponentially growing cultures and plated 
into 60-mm dishes in a total of 5 mL DMEM and at an initial concentration of 2 x 105 
cells per dish. Prior to cell plating, the culture medium was allowed to equilibrate in the 
incubator to attain the proper pH and temperature.  Four hours after cell culture initiation, 
the plated cells were treated with solutions of high purity L-ascorbic acid powder 
dissolved in PBS to produce concentrations of 100 µM, 1 mM or 10 mM in the culture 
medium.  A fourth group, not treated with ascorbic acid, served as the control.  Each of 
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the four groups was then incubated and allowed to grow.  Each day, two Petri dishes were 
selected from each treatment group.  The cells in these dishes were suspended and 
counted; and the number of cells per dish was calculated.  Cells from one dish per group 
were plated and a colony formation assay was performed to assess viability (see below 
for details).  Although this experiment was repeated twice, the first experiment followed 
the growth of the cells in cultures for only 2 days.  When the experiment was repeated, 
cell growth was studied daily for 4 days.  The duration of the study was chosen so that 
the cultures were followed throughout the period when the control cultures were expected 




To determine the effect of L-ascorbic acid on cellular radiosensitivity, 
exponentially growing stock EMT6 tumor cells were trypsinized, suspended in DMEM, 
counted and diluted to a concentration of 2 x 105 cells/mL.  One mL of cells was then 
plated into each of 18 Petri dishes containing 4 mL of DMEM that had been previously 
equilibrated to the proper pH and temperature.  Cultures were incubated for 3 days under 
the conditions described above, allowing the cells to reach the middle of the exponential 
growth phase prior to treatment.  After 3 days of growth, the medium was removed from 
all dishes and replaced with fresh DMEM.  Two treatment groups were then treated with 
solutions of high purity L-ascorbic acid powder dissolved in PBS to produce 
concentrations of either 1 mM or 10 mM in the culture medium. Cultures grown and 
treated under identical conditions but in the absence of L-ascorbic acid were used as 
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controls.  After 4 hours of exposure to ascorbic acid, cells were irradiated with doses of 
0.0, 2.5, 5.0, 7.5 or 10.0 Gray.  Immediately following irradiation, the medium was 
removed from the cultures, and the cells were washed, detached from the dish using 
0.05 percent trypsin, suspended in Waymouth’s medium and assayed for colony 




To determine the effect of L-ascorbic acid on clonogenic cell survival after 
treatment with doxorubicin, exponentially growing stock EMT6 tumor cells were 
trypsinized, suspended in DMEM, counted and diluted to a concentration of 2 x 105 
cells/mL.  One mL of cells was then plated into each of 15 Petri dishes containing 4 mL 
of DMEM that had been previously equilibrated to the proper pH and temperature.  
Cultures were incubated for 3 days allowing the cells to reach the middle of the 
exponential growth phase prior to treatment. After 3 days of growth, the medium was 
removed from all dishes and replaced with fresh DMEM.  Two treatment groups were 
then treated with solutions of high purity L-ascorbic acid powder dissolved in PBS to 
produce concentrations of either 1 mM or 10 mM in the culture medium. Cultures grown 
and treated under identical conditions but in the absence of L-ascorbic acid were used as 
controls.  After 2 hours of exposure to ascorbic acid, cells were treated with doxorubicin 
at concentrations of 0.0, 0.1, 0.4, or 1.6 µg/mL.  The doses of doxorubicin were selected 
based on prior studies (44).  After a total exposure time of 4 hours for ascorbic acid and 
2 hours for doxorubicin, the medium was removed from the cultures, and the cells were 
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washed, trypsinized, suspended in Waymouth’s medium and assayed for colony 
formation as described below.  This experiment was repeated three times. 
 
Colony Formation Assay 
 
To determine the survival of cells following treatment, colony formation assays 
were performed for all experiments described above.  After trypsinizatioin, the single-cell 
suspensions were counted using a Coulter Counter model ZBI.  Cell volume distributions 
were also determined to ensure that the cell counts were accurate and uncompromised by 
the clumping together of multiple cells.  Cells were then diluted and plated at low 
densities in Waymouth's medium.  Each treatment group was plated at multiple different 
densities to ensure that the resultant colonies would grow at such a density that individual 
colonies could be distinguished and counted.  Cells were then incubated and allowed to 
grow for 2 weeks at which time the colonies were washed, fixed with methanol and 
stained with crystal violet.  Each culture was projected on the wall for magnification and 
colonies of 50 cells or more were counted to determine the survival of cells with 
clonogenic capacity.  To ensure an objective count, colony counting was performed by 
lab workers other than this student investigator who were blinded to the treatments 
received by the cells in the different Petri dishes.  All the cultures from each experiment 





After all the cultures from an experiment were counted, the plating efficiency of 
each group was calculated.  Plating efficiency (PE) is the percentage of single cells plated 
that gives rise to colonies and is calculated by the following equation:   
 
100
plated cells ofnumber 
 formed colonies ofnumber PE x=  
 
In these experiments the mean plating efficiency of untreated control cells was 94.0% 
with a standard deviation of 15.1.   
 
A surviving fraction (SF) for each treatment group was determined by taking the 
ratio of the plating efficiency of the treated culture to that of the untreated control culture 
(i.e. cells treated with neither ascorbic acid nor radiation) plated in the same experiment 
on the same day: 
 
efficiency plating group control
efficiency plating grouptreatment SF =  
 
These surviving fractions were used to generate a radiation dose-response curve. This 
was accomplished by conducting a non-linear regression analysis using the StatMost 
Statistical Package to obtain the best fit of the following equation to the experimental 















This equation defines the surviving fraction (SF) at a given radiation dose (D).  The other 
variables in the equation define different parts of the dose-response curve.  D0 describes 
the slope of the linear segment of the curve.  Specifically, D0 is the dose required to 
reduce the surviving fraction by e1  on the linear portion of the curve.  The extrapolation 
number, n, is a description of the curve’s shoulder.  More precisely, n is the calculated 
surviving fraction at which the linear section of the survival curve, extrapolated back to 
zero dose, hits the y-axis.  Because vitamin C alone was found to produce a small toxic 
effect in the radiation studies, the SF’s of the groups treated with vitamin C plus radiation 
were normalized using the PE’s of the vitamin C-treated cultures before these curves 
were fitted.      
 
To quantify the extent to which vitamin C alters the radiation response of EMT6 
cells, data from the dose-response curve was used to calculate the dose-modifying factor 
(DMF) for ascorbic acid.  DMF for radioprotectors is defined as the ratio of the dose of 
radiation with the modifying agent (i.e. vitamin C) to the dose of radiation without the 
agent that results in the same level of cell survival (20): 
 
0.1 of SFan in  resultingagent  modifying without doseradiation 
0.1 of SFan in  resultingagent  modifying with doseradiation DMF =  
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DMF’s were calculated by extrapolating the computer-fitted curves to a surviving 
fraction of 0.1.  A DMF greater than 1.0 indicates protection, whereas a DMF less than 
1.0 indicates sensitization.  The Wilcoxon test was performed using the Statmost 
Statistical Package to determine whether the differences between the curves were 






Preliminary growth studies examined the growth curves for EMT6 cells to 
determine the effects of different doses of ascorbic acid on the growth of these cells 
in vitro.  The three different concentrations of L-ascorbic acid used in the experiment 
were 100 µM, 1 mM and 10 mM.  Cells grown under identical conditions but in the 
absence of ascorbic acid were used as controls.  Figure 3 shows the growth curve of each 
of the four groups of cells studied.  No error bars are shown because this graph represents 
data from one single experiment.  When EMT6 cultures were grown in the presence of 
1 mM or 10 mM concentrations of vitamin C, there was a significant reduction in cell 
growth compared to control cultures.  The cells grown in the presence of the smallest 
concentration of vitamin C tested, 100 µM, showed a slight decrease in growth.  This 
slight reduction in cell growth, however, cannot be tested for statistical significance based 
on data from only one experiment.   
 
 After counting the cells in each of the four groups to determine cell growth, the 
cells were then assayed for clonogenic capacity.  On each of the 4 days of the experiment, 
cells from one dish per treatment group were plated in fresh media not containing any 
ascorbic acid.  The cells were incubated for 2 weeks and were then washed, fixed and 
stained.  Colonies of 50 cells or more were counted.  In this way, the clonogenic capacity 
was determined for cells after exposure to ascorbic acid for 1, 2, 3 or 4 days for each of 










FIGURE 3.  Growth study of EMT6 cells grown in the presence of different 
concentrations of L-ascorbic acid.  Points are arithmetic means of cell numbers from 2 
dishes, obtained in a single experiment.  Key:  λ represents control cells;  represents 
cells treated with 100 µM L-ascorbic acid; ▼ represents cells treated with 1 mM 
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FIGURE 4.  Survival of EMT6 cells grown in the presence of different 
concentrations of L-ascorbic acid.  Each point is the surviving fraction of cells from 
one dish, obtained in a single experiment.  Key:  λ represents control cells;  represents 
cells treated with 100 µM L-ascorbic acid; ▼ represents cells treated with 1 mM 
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comparing the plating efficiencies of the treatment groups to that of the control group.  
Figure 4 illustrates these surviving fractions.  The cells exposed to 1 mM or 10 mM 
vitamin C show a significant reduction in clonogenic capacity compared to cells in the 
control group.  This means that the presence of high concentrations of vitamin C in this 
study not only caused a reduction in cell proliferation (see Figure 3), but also reduced the 
capacity of existing cells to produce new colonies even after the vitamin was removed 
from the culture medium (see Figure 4).  Clonogenicity was seen to improve, however, 
with increasing exposure time to the vitamin as illustrated by the positive slopes of the 
lines graphed in Figure 4. 
 
In summary, results of a preliminary growth study suggest a slightly toxic effect 
of 100 µM vitamin C in comparison to control, and a significant toxicity of 1 mM and 
10 mM L-ascorbic acid causing a reduction in both cell proliferation and clonogenic 
capacity.  The growth study results presented above were considered when choosing the 
concentrations of ascorbic acid to be used in subsequent studies of the effect of vitamin C 
on the outcomes of treatment with radiation and doxorubicin.  Concentrations of 1 mM 
and 10 mM L-ascorbic acid were selected for these subsequent experiments despite the 
demonstrated toxicity of the vitamin at these levels.  It is important to note that in the 
preliminary growth study, cells were exposed to ascorbic acid for durations of 1, 2, 3 or 4 
day, whereas the cells in subsequent experiments were exposed to the vitamin for only 





Figure 5 shows data from experiments examining the effects of two different high 
concentrations of L-ascorbic acid on the cellular radiosensitivity of EMT6 tumor cells. 
Data points on the graph represent the geometric means ± the standard errors of the mean 
(S.E.M.s) of surviving fractions determined in three independent experiments.  Following 
convention, radiation dose is plotted along the x-axis on a linear scale while surviving 
fraction is plotted along the y-axis on a logarithmic scale. The curves representing cells 
treated with 1 mM and 10 mM vitamin C have been corrected for ascorbic acid toxicity.  
The surviving fractions for cells treated with vitamin C alone were 0.86 and 0.56 for cells 
treated with 1 mM and 10 mM vitamin C, respectively.  As expected, cell survival 
decreases with increasing dose of ionizing radiation as illustrated by the down-sloping 
curves in all three groups.   
 
The figure shows a significant change in the radiosensitivity of cultures treated 
with radiation plus vitamin C as compared to those treated with radiation alone.  The 
survival curve for cultures treated with 1 mM ascorbic acid lies above the control curve 
on the graph.  The difference between these two curves was found to be statistically 
significant (p = 0.012).  The survival curve for cultures treated with 10 mM ascorbic acid 
lies even further above the control curve (p = 0.003) and well above the curve 
representing survival of cells treated with the lower dose of vitamin C (p = 0.011).  This 









FIGURE 5.  Effects of L-ascorbic acid on the radiation dose-response curve of 
exponentially growing EMT6 cells.  Points are geometric means ± standard errors of the 
mean (S.E.M.s) of survivals determined in 3 independent experiments.  Curves were 
fitted as described in the Material and Methods section.  Key:  λ represents control cells; 
 represents cells exposed to 1 mM L-ascorbic acid for 4 hours immediately prior to 
irradiation; ▼ represents cells exposed to 10 mM L-ascorbic acid for 4 hours 
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indicates a protective effect of the vitamin.  Furthermore, this protective effect was 
greatest at the highest concentration of vitamin C tested.   
 
The dose-modifying factor (DMF), the ratio of the dose of radiation with the 
modifying agent to the dose of radiation without the agent (in this case, vitamin C) that 
results in the same level of cell survival (in this case, a surviving fraction of 0.10), was 
calculated from these survival curves.  A DMF greater than 1.0 indicates protection, 
whereas a DMF less than 1.0 indicates sensitization.  The DMF for 1 mM ascorbic acid 
was calculated to be 1.23.  This means that a concentration of 1 mM vitamin C alters the 
antineoplastic effects of radiation such that in order to achieve the same level of cell 
damage, a dose of radiation 23 percent higher would need to be given.  The calculated 
DMF for 10 mM ascorbic acid was 1.37, indicating that at this higher concentration of 
vitamin C the radiation dose would need to be 37 percent higher in order to result in the 
same level of radiation-induced damage.  In summary, the results of radiation 
experiments show that mega-doses of vitamin C protect EMT6 mouse mammary tumor 




Figure 6 shows data from experiments examining the effects of two different high 
concentrations of L-ascorbic acid on the survival of EMT6 tumor cells treated with 
doxorubicin.  Data points on the graph represent the geometric means ± S.E.M.s of 
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surviving fractions determined in three independent experiments.  The surviving fractions 
for cells treated with vitamin C alone were 1.03 and 0.91 for cells treated with 1 mM and 
10 mM vitamin C, respectively.  Doxorubicin dose is plotted along the x-axis; surviving 
fraction is plotted along the y-axis.  Both doxorubicin dose and surviving fraction are 
shown on a logarithmic scale.  Cell survival decreases with increasing dose of 
doxorubicin in all three groups, illustrated by the down-sloping curves.   
 
There is no difference in the survival curves of cultures treated with 0, 1, or 
10 mM ascorbic acid, as can be seen from the overlapping error bars in the figure.  The 
Wilcoxon test was performed and no statistically significant difference was found 
between the control group and the cells exposed to 1 mM ascorbic acid (p = 1.0), between 
the control group and the cells exposed to 10 mM ascorbic acid (p = 0.75), or between the 
cells exposed to 1 mM and 10 mM ascorbic acid (p = 0.75).  This data suggests that 
L-ascorbic acid has no effect on the sensitivity of EMT6 mouse mammary carcinoma 










FIGURE 6.  Effects of L-ascorbic acid on the response of exponentially growing 
EMT6 cells to doxorubicin.  Points are geometric means ± S.E.M.s of survivals 
determined in 3 independent experiments.  Key:  λ represents control cells;  represents 
cells exposed to 1 mM L-ascorbic acid for 4 hours; ▼ represents cells exposed to 10 mM 
L-ascorbic acid for 4 hours.  All cells were exposed to the indicated dose of doxorubicin 
for 2 hours. 
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 The aim of this research was to elucidate any modulatory effect ascorbic acid may 
have on the cytotoxic effects of radiation or doxorubicin on EMT6 mouse mammary 
carcinoma cells.  The findings from the radiation studies reported here demonstrate that 
vitamin C decreases the radiosensitivity of EMT6 tumor cells. The dose-modifying 
factors for 1 mM and 10 mM ascorbic acid as compared to controls were 1.23 and 1.37, 
respectively.  This indicates a radioprotective effect of vitamin C.  Furthermore, greater 
radioprotective effect is seen with the higher concentration of vitamin C.  Specifically, 
the data show that in order to achieve the same level of cell damage in the presence of 
1 mM or 10 mM vitamin C, one would have to administer a dose of radiation 1.23 or 1.37 
times that actually given, respectively.  No chemomodulatory effects of vitamin C were 
observed in the doxorubicin studies.   
 
It is important to view these results in the context of other research that has been 
done on vitamin C and its potential role as an adjuvant treatment in cancer therapy.  The 
clinical question is essentially this:  given the well-established antioxidant properties of 
vitamin C, does vitamin C reduce the toxicity of radiotherapy or chemotherapy to normal 
tissues without compromising their antineoplastic effects?  Furthermore, if this question 
cannot be definitively answered on the basis of current medical research, what 
recommendation about vitamin C supplementation should be made to cancer patients 
undergoing conventional treatment? 
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 Because the results of this thesis support the hypothesis that vitamin C alters the 
antitumor effects of radiation but not of doxorubicin, this discussion will focus on the 
existing evidence for and debate over whether vitamin C is beneficial to cancer patients 
undergoing radiotherapy.  Overall, in vitro and animals studies investigating the 
interaction between ascorbic acid and radiotherapy have been contradictory and 
inconclusive (24-31).  Particularly concerning for its clinical implications is the fact that 
some studies not only fail to find a beneficial effect of vitamin C, but rather demonstrate 
that vitamin C may actually cause harm by reducing the antineoplastic efficacy of 
conventional therapies (24, 37). 
 
 Of course, although cell culture and animal data are important in deciphering the 
interactions of vitamin C with conventional cancer therapies, a randomized, double-blind, 
placebo-controlled clinical trial is necessary to definitively answer the question of 
whether vitamin C supplementation has a role to play in cancer treatment.  Such a trial 
would need to include large numbers of patients to have sufficient power to detect small 
but important differences between the vitamin C and control groups.  To date, no such 
clinical trial has been done.  The closest approximation is an historical cohort study 
conducted in 2002 by Lesperance et al. (45).  In this study, survival and recurrence 
outcomes for 90 women with unilateral non-metastatic breast cancer who had been 
prescribed mega-doses of vitamin C in addition to other vitamins and minerals while 
concurrently undergoing conventional therapy were compared to 180 rigorously-matched 
controls.  Patients were not excluded from the study based on the type of conventional 
treatment received.  Sixty-nine percent of study subjects were treated with systemic 
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therapy, with or without radiation or surgery.  Sixty-five percent were treated with 
radiation, with or without systemic therapy or surgery; the radiation status of 6 percent of 
the patients is unknown.  Results showed shorter disease-free survival and breast cancer-
specific survival for the mega-dose vitamin group compared to controls.  Although these 
differences were not statistically significant (p = 0.07 for disease-free survival; p = 0.16 
for breast cancer-specific survival) they none-the-less reinforce the concern that the use 
of high-dose vitamin C during cancer therapy cannot be assumed to be benign.    
 
 As always in the quest to find more efficacious and better-tolerated treatments for 
cancer, the concept of the therapeutic ratio is both clinically relevant and important.  The 
therapeutic ratio is defined as the maximum tolerated dose of a drug to the effective dose.  
When assessing the clinical benefit of any potential therapy modulator, such as vitamin C, 
it is imperative to consider the effect on the response of the tumor as well as the effect on 
the response of the dose-limiting normal tissues.  Treatments that lead to equal changes in 
tumor response and dose-limiting normal tissue response will have a net effect of zero 
improvement in outcome. Only those treatments that increase tumor response relative to 
the dose-limiting normal tissue response will result in therapeutic gain (22).  Following 
this logic, in order to demonstrate the value of vitamin C as an adjuvant therapy to 
radiation, it is not sufficient to show that vitamin C protects dose-limiting normal tissues 
from radiation injury.  One must also provide evidence that there is relative protection of 
these normal tissues compared to the tumor. 
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 The scientific and medical data currently available do not provide sufficient 
evidence to support the claim that vitamin C improves the therapeutic ratio of either 
radiation or doxorubicin.  In fact, results of the research conducted for this thesis suggest 
that high-dose ascorbic acid may actually decrease the efficacy of radiotherapy.  Given 
the high prevalence of complementary and alternative medicine use among cancer 
patients, it is extremely important that clinicians address the topic of vitamin 
supplementation with their patients who are undergoing standard therapy.   In her recent 
review article of antioxidants during chemotherapy and radiotherapy, D’Andrea cautions 
that if antioxidants compromise the efficacy of cancer treatment by even a few 
percentage points, their use could lead to hundreds or thousands of deaths per year (46).  
Until proven otherwise, high-dose vitamin C must be considered potentially dangerous 
when taken by cancer patients concomitantly with radiation, and patients should be 
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